MENU
+Compare
ALBBY
Stock ticker: OTC
AS OF
Oct 7 closing price
Price
$15.96
Change
-$1.26 (-7.32%)
Capitalization
12.98B

ALBBY Alibaba Health Information Technology Ltd Forecast, Technical & Fundamental Analysis

Alibaba Health is of one of China's leading e-commerce platform specializing in healthcare-related products, including prescription drugs, OTC drugs, traditional Chinese medicine, health foods, and so on... Show more

ALBBY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for ALBBY with price predictions
Feb 02, 2026

ALBBY in downward trend: price may drop because broke its higher Bollinger Band on January 12, 2026

ALBBY broke above its upper Bollinger Band on January 12, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 27 similar instances where the stock broke above the upper band. In of the 27 cases the stock fell afterwards. This puts the odds of success at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 14 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 20 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 02, 2026. You may want to consider a long position or call options on ALBBY as a result. In of 69 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ALBBY just turned positive on January 05, 2026. Looking at past instances where ALBBY's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

ALBBY moved above its 50-day moving average on January 12, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ALBBY crossed bullishly above the 50-day moving average on January 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 133 cases where ALBBY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ALBBY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.459) is normal, around the industry mean (3.133). P/E Ratio (49.886) is within average values for comparable stocks, (42.751). Projected Growth (PEG Ratio) (1.016) is also within normal values, averaging (1.256). Dividend Yield (0.000) settles around the average of (0.028) among similar stocks. P/S Ratio (2.915) is also within normal values, averaging (30.242).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALBBY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ALBBY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry DrugstoreChains

Profile
Fundamentals
Details
Industry
N/A
Address
Guanghua Road
Phone
N/A
Employees
1560
Web
https://www.alihealth.cn
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
USAI41.560.81
+1.98%
Pacer American Energy Independence ETF
IDEQ33.190.25
+0.76%
Lazard Active ETF TR
BSCU16.89-0.02
-0.09%
Invesco BulletShares 2030 Corp Bd ETF
XDTE39.79-0.35
-0.87%
Roundhill S&P 500 0DTE Cov Cll Strat ETF
LGHT9.57-0.27
-2.75%
Langar Global HealthTech ETF

ALBBY and Stocks

Correlation & Price change

A.I.dvisor tells us that ALBBY and ALBHF have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ALBBY and ALBHF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALBBY
1D Price
Change %
ALBBY100%
N/A
ALBHF - ALBBY
32%
Poorly correlated
N/A
RDGT - ALBBY
7%
Poorly correlated
-3.97%
PETS - ALBBY
2%
Poorly correlated
+1.95%
MSMKF - ALBBY
0%
Poorly correlated
N/A
HEWA - ALBBY
-1%
Poorly correlated
N/A
More